Biofrontera Inc. (BFRI) Stock

Biofrontera Inc. is a biopharmaceutical company focused on the commercialization of pharmaceutical products targeting dermatological conditions within the United States. Central to its offerings is Ameluz, a prescription drug utilized in conjunction with the RhodoLED lamp series for photodynamic therapy. This treatment is specifically designed for both lesion-directed and field-directed therapy of actinic keratosis, particularly on the face and scalp. Additionally, Biofrontera Inc. provides Xepi, a prescription cream tailored for treating impetigo, underscoring its commitment to addressing various dermatological needs.

Founded in 1997 and headquartered in Woburn, Massachusetts, Biofrontera Inc. has established itself as a pivotal player in the dermatological pharmaceutical market. The company's portfolio emphasizes innovative therapeutic solutions aimed at enhancing patient outcomes and quality of life. With a robust pipeline and a strong emphasis on research and development, Biofrontera Inc. continues to expand its footprint in the dermatology sector, leveraging its expertise to deliver effective treatments that meet the evolving needs of patients and healthcare providers alike.

Through its dedication to advancing dermatological care, Biofrontera Inc. remains at the forefront of pharmaceutical innovation. By combining scientific expertise with a patient-centric approach, the company remains committed to improving treatment options and setting new standards in dermatological healthcare.